{"classes":[{"categories":[{"measurements":[{"comment":"A range was not available for a single participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"1.07"},{"comment":"A range was not available for a single participant.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"3.98"},{"comment":"A range was not available for a single participant.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"2.02"},{"groupId":"OG003","lowerLimit":"0.983","upperLimit":"23.7","value":"1.58"},{"groupId":"OG004","lowerLimit":"0.500","upperLimit":"6.10","value":"1.00"},{"groupId":"OG005","lowerLimit":"0.500","upperLimit":"6.00","value":"1.13"},{"groupId":"OG006","lowerLimit":"0.517","upperLimit":"5.90","value":"1.12"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"57"},{"groupId":"OG006","value":"13"}],"units":"Participants"}],"description":"tmax was defined as the time to the maximum observed plasma concentration.","dispersionType":"Full Range","groups":[{"description":"Participants self-administered oral pemigatinib 1 milligram (mg) once daily (QD) on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG000","title":"Part 1: Intermittent Pemigatinib 1 mg QD"},{"description":"Participants self-administered oral pemigatinib 2 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG001","title":"Part 1: Intermittent Pemigatinib 2 mg QD"},{"description":"Participants self-administered oral pemigatinib 4 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG002","title":"Part 1: Intermittent Pemigatinib 4 mg QD"},{"description":"Participants self-administered oral pemigatinib 6 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break.","id":"OG003","title":"Part 1: Intermittent Pemigatinib 6 mg QD"},{"description":"Participants self-administered intermittent or continuous oral pemigatinib 9 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 9 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 9 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG004","title":"Parts 1 and 2: Intermittent/Continuous Pemigatinib 9 mg QD"},{"description":"Participants self-administered intermittent or continuous oral pemigatinib 13.5 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in either Part 1 or Part 2. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG005","title":"Parts 1 and 2: Intermittent/Continuous Pemigatinib 13.5 mg QD"},{"description":"Participants self-administered intermittent or continuous oral pemigatinib 20 mg QD in either Part 1 or Part 2. Intermittent dosing: participants self-administered oral pemigatinib 20 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule in Part 1. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 20 mg QD on Days 1 through 21 of each 21-day cycle in either Part 1 or Part 2.","id":"OG006","title":"Parts 1 and 2: Intermittent/Continuous Pemigatinib 20 mg QD"}],"paramType":"MEDIAN","populationDescription":"PK/PD Population. Only participants with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Part 1: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14. Part 2: predose on Cycle 1 Days 8 and 14; 0.5, 1, 2, 4, 6, and 8 hours post-dose on Cycle 1 Day 14","title":"Parts 1 and 2: Tmax After Once Daily Dosing of Pemigatinib as Monotherapy on Cycle 1 Days 8 and 14 (Steady State)","type":"SECONDARY","unitOfMeasure":"hr"}